EDEN PRAIRIE, Minn., March 26, 2019 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), today announced the publication of
“Ultrafiltration vs. Diuretics for Treatment of Fluid Overload in Patients with Heart Failure: A Hospital Cost
Analysis” in the Journal of Medical Economics showing that the use of ultrafiltration therapy with the company’s
Aquadex Flex Flow System in heart failure patients reduces hospital readmissions and durations of stay which lowers hospital costs
over a 90-day period, compared to diuretic therapy.
“We have for some time highlighted that one of the key advantages to ultrafiltration therapy with the Aquadex system was the
cost savings to the hospital and the healthcare system in general,” said John Erb, chairman and CEO of CHF Solutions. “It is
gratifying to have this claim validated in a peer-reviewed academic journal that covers economic assessments of therapeutics and
medical device interventions. We continue to believe that ultrafiltration therapy provides a much needed clinical alternative
to diuretic therapy that also provides important economic benefits.”
The study examined clinical data from the literature and hospital data from the Healthcare Cost and Utilization Project to
follow a decision analytic framework outlining treatment decision, probabilistic outcomes and associated costs for treating heart
failure patients with fluid overload (hypervolemia) with either ultrafiltration or diuretic therapy. Results showed that
while initial healthcare costs associated with ultrafiltration therapy were higher, fluid removal with ultrafiltration, such as
with the Aquadex Flex Flow system, reduced hospital readmissions, leading to a cost savings of $3,975, or nearly 15 percent,
compared to diuretic therapy. The study abstract can be accessed via https://www.ncbi.nlm.nih.gov/pubmed/30775944.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for
aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be
administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal
therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration,
and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis,
Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the
Nasdaq Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, including without limitation, the benefits of ultrafiltration therapy as compared to diuretic
therapy. Forward-looking statements are predictions, projections and other statements about future events that are based on
current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause
actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those
risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient
funds necessary for our anticipated operations, benefits of our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not
assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com
